TABLE 2.
Compound | Concn (μg/ml) | Precursora
|
|||||
---|---|---|---|---|---|---|---|
[3H]thymidine
|
[3H]uridine
|
3H-labeled amino acids
|
|||||
% Uptakeb | % Incorpc | % Uptake | % Incorp | % Uptake | % Incorp | ||
3 | 128 | 2 | 6 | 2 | 4 | 11 | 41 |
16 | 64 | 60 | 77 | 67 | 50 | 72 | |
4 | 128 | 1 | 12 | 3 | 19 | 11 | 42 |
16 | 50 | 43 | 52 | 48 | 60 | 45 | |
5 | 128 | 2 | 2 | 8 | 1 | 27 | 28 |
16 | 1 | 2 | 2 | 1 | 19 | 11 | |
6 | 128 | 6 | 8 | 8 | 6 | 16 | 2 |
16 | 84 | 52 | 66 | 26 | 48 | 2 | |
Ciprofloxacin | 0.25 | 60 | 4 | 103 | 90 | 105 | 96 |
Rifampin | 0.25 | 159 | 113 | 46 | 2 | 85 | 22 |
Chloramphenicol | 8 | 112 | 85 | 109 | 100 | 50 | 27 |
After 10 min of drug treatment and 5 min of pulse labeling. Results are presented as a percentage of untreated-control results.
Total radiolabeled precursor remaining in the cells after an instant saline wash.
Precursor incorporated into TCA-precipitable material. Incorp, incorporation.